The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma

International Journal of Pharmaceutics

Volumn 473, Issue 1-2, 2014, Pages 326-333

  Alavizadeh, Seyedeh Hoda ^a   Badiee, Ali ^b   Golmohammadzadeh, Shiva ^b   Jaafari, Mahmoud Reza ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C26 colon carcinoma; Cancer treatment; Cisplatin; Liposome; Phase transition temperature

Indexed keywords

1,2 DIMYRISTOYL SN GLYCERO 3 PHOSPHOCHOLINE; CHOLESTEROL; CISPLATIN; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; HYDROGENATED SOY PHOSPHATIDYLCHOLINE; LIPOSOME; MACROGOL DERIVATIVE; PHOSPHATIDYLCHOLINE; SOY PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PHOSPHOLIPID; SPI-77, LIPOSOMAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY TEMPERATURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CARCINOMA CELL; CELL DEATH; CELL PROLIFERATION; CIRCULATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG RETENTION; DRUG SOLUBILITY; ENCAPSULATION; FEMALE; LIPID BILAYER; LIPOSOMAL DELIVERY; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PHASE TRANSITION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TRANSITION TEMPERATURE; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL SURVIVAL; CHEMISTRY; COLON; COLONIC NEOPLASMS; DRUG EFFECTS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTEROL; CISPLATIN; COLON; COLONIC NEOPLASMS; FEMALE; LIPOSOMES; MICE, INBRED BALB C; PHASE TRANSITION; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; TUMOR BURDEN;

EID: 84904964960     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.07.020     Document Type: Article

References (56)

1. C. Allen, N. Dos Santos, R. Gallagher, G.N.C. Chiu, Y. Shu, W.M. Li, S.A. Johnstone, A.S. Janoff, L.D. Mayer, and M.S. Webb Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol) Biosci. Rep. 22 2002 225 250
2. T. Allen, and P. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818
3. M. Amin, A. Badiee, and M. Jaafari Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C26 colon carcinomas Int. J. Pharm. 458 2013 324
4. M. Anderson, and A. Omri The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations Drug Deliv. 11 2004 33
5. S. Bandak, D. Goren, A. Horowitz, D. Tzemach, and A. Gabizon Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models Anticancer Drugs 10 1999 911
6. Y. Barenholz Liposome application: problems and prospects Curr. Opin. Colloid Interface Sci. 6 2001 66 77
7. B. Baruah, and A. Surin Interaction of liposome encapsulated cisplatin with biomolecules J. Biol. Inorg. Chem. 17 2012 899 910
8. T. Boulikas Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin Expert Opin. Investig. Drugs 18 2009 1197
9. T. Boulikas, and M. Vougiouka Recent clinical trials using cisplatin carboplatin and their combination chemotherapy drugs (review) Oncol. Rep. 11 2004 559 595
10. T. Boulikas, G.P. Stathopoulos, N. Volakakis, and M. Vougiouka Systemic lipoplatin infusion results in preferential tumor uptake in human studies Anticancer Res. 25 2005 3031 3039
11. G. Charrois, and T. Allen Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer Biochim. Biophys. Acta 1663 2004 167
12. J. De Gier, J. Mandersloot, and L. van Deenen Lipid composition and permeability of liposomes Biochim. Biophys. Acta 150 1968 666
13. D. Drummond, O. Meyer, K. Hong, D. Kirpotin, and D. Papahadjopoulos Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 51 1999 691 743
14. A. Fahr, P.V. Hoogevest, S. May, N. Bergstrand, and M.L. Leigh Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery Eur. J. Pharm. Sci. 26 2005 251 265
15. F.F. Farris, R.L. Dedrick, and F.G. King Cisplatin pharmacokinetics: applications of a physiological model Toxicol. Lett. 43 1988 117 137
16. M. Grit, and D.J.A. Crommelin Chemical stability of liposomes: implications for their physical stability Chem. Phys. Lipids 64 1993 3 18
17. I. Hamelers, E. Van Loenen, R. Staffhorst, B. de Kruijff, and A. de Kroon Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin Mol. Cancer Ther. 5 2006 2007
18. K. Harrington, C. Lewanski, A. Northcote, J. Whittaker, H. Wellbank, R. Vile, A. Peters, and J. Stewart Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. 12 2001 493
19. Z. Huang, and M. Szoka Jr. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties J. Am. Chem. Soc. 130 2008 15702
20. Z. Huang, M.R. Jaafari, and F.C. Szoka Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery Angew. Chem. 121 2009 4210 4213
21. M. Iman, Z. Huang, F.C. Szoka Jr., and M.R. Jaafari Characterization of the colloidal properties in vitro antifungal activity, antileishmanial activity and toxicity in mice of a distigmasterylhemisuccinoyl-glycero-phosphocholine liposome-intercalated amphotericin B Int. J. Pharm. 408 2011 163 172
22. M.L. Immordino, F. Dosio, and L. Cattel Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomed. 1 2006 297
23. K. Jacobson, and D. Papahadjopoulos Phase transitions and phase separations in phospholipid membranes induced by changes in temperature, pH, and concentration of bivalent cations Biochemistry 14 1975 152
24. R. Jain Transport of molecules across tumor vasculature Cancer Metastasis Rev. 6 1987 559
25. A. Johnsson, P. Höglund, A. Grubb, and E. Cavallin-Ståhl Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus Cancer Chemother. Pharmacol. 39 1996 25
26. C. Kirby, J. Clarke, and G. Gregoriadis Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro Biochem. J. 186 1980 591 598
27. G. Kong, and M. Dewhirst Hyperthermia and liposomes Int. J. Hyperth.: Off. J. Eur. Soc. Hyperth. Oncol. 15 1999 345
28. D. Lasic, and D. Papahadjopoulos Liposomes revisited Science 267 1995 1275
29. L. Levin, and W.M. Hryniuk Dose intensity analysis of chemotherapy regimens in ovarian carcinoma J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 5 1987 756 767
30. H.J. Lim, D. Masin, T.D. Madden, and M.B. Bally Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone J. Pharmacol. Exp. Ther. 281 1997 566 573
31. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzym. Regul. 41 2001 189 207
32. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
33. H. Maeda, G. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409
34. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Deliv. Rev. 65 2013 71
35. T.J. Meerum, M. Tibben, H. Welbank, J. Schellens, and J. Beijnen Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry Fresenius J. Anal. Chem. 366 2000 298
36. T.J. Meerum, G. Groenewegen, D. Pluim, M. Maliepaard, M. Tibben, A. Huisman, H.W. ten Bokkel, M. Schot, H. Welbank, and E. Voest Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin Cancer Chemother. Pharmacol. 49 2002 201
37. V. Murray, J. Whittaker, M. Temple, and W. McFadyen Interaction of 11 cisplatin analogues with DNA: characteristic pattern of damage with monofunctional analogues Biochim. Biophys. Acta 1354 1997 261
38. M. Newman, G. Colbern, P. Working, C. Engbers, and M. Amantea Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice Cancer Chemother. Pharmacol. 43 1999 1
39. V. Pinzani, F. Bressolle, I. Johanne Haug, M. Galtier, J.P. Blayac, and P. Balmès Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review Cancer Chemother. Pharmacol. 35 1994 1 9
40. M. Pons, M. Foradada, and J. Estelrich Liposomes obtained by the ethanol injection method Int. J. Pharm. 95 1993 51 56
41. T. Schluep, J. Hwang, J. Cheng, J.D. Heidel, D.W. Bartlett, B. Hollister, and M.E. Davis Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models Clin. Cancer Res.: Off. J. Am. Assoc. Cancer. Res. 12 2006 1606 1614
42. A. Seelig, and J. Seelig Effect of a single cis double bond on the structures of a phospholipid bilayer Biochemistry 16 1977 45
43. J.H. Senior Fate and behavior of liposomes in vivo: a review of controlling factors Crit. Rev. Ther. Drug Carr. Syst. 3 1987 123 193
44. A. Sharma, and U.S. Sharma Liposomes in drug delivery: progress and limitations Int. J. Pharm. 154 1997 123 140
45. G. Stathopoulos Liposomal cisplatin: a new cisplatin formulation Anticancer Drugs 21 2010 732
46. G.P. Stathopoulos, T. Boulikas, M. Vougiouka, G. Deliconstantinos, S. Rigatos, E. Darli, V. Viliotou, and J.G. Stathopoulos Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study Oncol. Rep. 13 2005 589 595
47. G.P. Stathopoulos, T. Boulikas, M. Vougiouka, S.K. Rigatos, and J.G. Stathopoulos Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study Oncol. Rep. 15 2006 1201 1204
48. J.M. Terwogt, M.M. Tibben, H. Welbank, J.H. Schellens, and J.H. Beijnen Validated method for the determination of platinum from a liposomal source (SPI077) in human plasma using graphite furnace Zeeman atomic absorption spectrometry Fresenius J. Anal. Chem. 366 2000 298 302
49. V. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145
50. A. Vekris, D. Meynard, M.C. Haaz, M. Bayssas, J. Bonnet, and J. Robert Molecular determinants of the cytotoxicity of platinum compounds Cancer Res. 64 2004 356
51. R. Weiss, and M. Christian New cisplatin analogues in development. A review Drugs 46 1993 360
52. S. White, P. Lorigan, G. Margison, J. Margison, F. Martin, N. Thatcher, H. Anderson, and M. Ranson Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer Br. J. Cancer 95 2006 822
53. J. Woo, G.N.C. Chiu, G. Karlsson, E. Wasan, L. Ickenstein, K. Edwards, and M.B. Bally Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes Int. J. Pharm. 349 2008 38 46
54. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent Cisplatin nephrotoxicity: a review Am. J. Med. Sci. 334 2007 115
55. W. Zamboni, A. Gervais, M. Egorin, J. Schellens, E. Zuhowski, D. Pluim, E. Joseph, D. Hamburger, P. Working, and G. Colbern Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma Cancer Chemother. Pharmacol. 53 2004 329
56. N. Zisman, N. Dos Santos, S. Johnstone, A. Tsang, D. Bermudes, L. Mayer, and P. Tardi Optimizing liposomal cisplatin efficacy through membrane composition manipulations Chemother. Res. Pract. 2011 2011 7 pages